Citations

Clear

1526 citation(s) found for "Sun, Yu".

Abstract 4366034: Fibroblast Dysregulation Drives Atrial Fibrosis of Sorbs2 Knockout Mice
Zou, Tian, Sun, Xiaojing , Lu, Tong , Lee, Hon-Chi

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4366034 Get It

Background: We have previously reported that Sorbs2 (sorbin and SH3 domain 2) knockout mice have significant cardiac structural and electrical remodeling, including atrial enlargement and fibrosis. The mechanisms of such changes were unknown. Hypothesis: We hypothesized that loss of Sorbs2 in cardiac fibroblasts promotes profibrotic signaling pathways and alters the balance between matrix metalloproteinases (MMPs), and their inhibitors (TIMPs) resulting in excessive collagen deposition in the atria. Methods: We used Sorbs2 global knockout ( Sorbs2 KO) mice and age-matched wild-type (WT) controls at 4 to 5 months of age. Left atrial fibrosis was quantitated by Masson's trichrome staining in serial sections. Scratch wound healing assays and transwell migration assays were performed in isolated Sorbs2 KO and WT atrial fibroblasts. Protein expression was determined by Western blots. Interleukin-6 (IL-6) production in cultured fibroblast supernatants was measured by ELISA. Results: Sorbs2 KO mice showed significant increase in atrial diameter (16.6 ± 1.5 mm vs 12.0 ± 1.1 mm in WT; n=3, p < 0.05) and atrial fibrosis (fraction of fibrotic areas: 18.6± 2.9 % vs. 7.6 ± 0.9 % in WT; p < 0.01). Collagen 1 and collagen 3 protein levels in Sorbs2 KO mouse atria were 1.8-fold and 1.7-fold higher than those of WT respectively. Sorbs2 KO atrial fibroblasts showed impaired function with significantly reduced migration and slower scratch-wound closure (migration area after 24h: 18.5 ± 3.8 % vs 70.1 ± 6.7 % in WT; n=6, p < 0.01).Moreover, transforming growth factor β1 (TGF-β1), α-smooth muscle actin, and periostin expression levels were significantly reduced in isolated fibroblasts and atrial myocardia from Sorbs2 KO mice, suggesting that fibrosis is not caused by TGF-b1-dependent mechanisms or from myofibroblast transformation. Analysis of ECM proteins showed significant downregulation of MMP1 and MMP3 but upregulation of TIMP1, while TIMP3 was unchanged. Consistent with a pro-inflammatory phenotype, Sorbs2 KO atrial fibroblasts secreted higher IL-6 levels at baseline (3303± 463 pg/mL vs. 2075 ± 731 pg/mL in WT; n=6, p < 0.01) and with LPS stimulation (7791 ± 604 pg/mL vs. 5588 ± 763 pg/mL in WT; n=6, p < 0.01). Conclusion: Sorbs2 deficiency is associated with abnormal atrial fibroblast function showing impaired migration and scratch wound healing, as well as increased IL-6 production and imbalanced MMP/TIMP. These changes result in collagen accumulation and enhanced fibrosis.
Abstract 4344937: The Impact of English Language Proficiency on Outcomes After Cardiovascular Surgery
Yasui, Osamu Winget , Powell, Johnny, Sun, Louise Y. , Ríos, José , Castro, Samuel, Powell, Johnny, Milam, Adam J.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4344937 Get It

Introduction: Language barriers represent an often-overlooked determinant of health equity. This study evaluates the impact of limited English proficiency (LEP) on major adverse cardiac events (MACE) and mortality in patients undergoing cardiovascular surgery. We hypothesized that patients with LEP have a higher incidence of adverse outcomes compared to English proficient patients. Methods: We conducted a retrospective cohort study using Cosmos, a longitudinal national electronic health record dataset. Patients were classified as having LEP if their record indicated a preferred language other than English. Adult patients aged 18-95 years who underwent coronary artery bypass grafting, valvular surgery, or thoracic aorta surgery in the United States (January 2016 - February 2025) were included. Exclusion criteria were missing language data, first in-person encounter <1 year prior to surgery, history of metastatic cancer or dialysis, and nursing home residence within 90 days of surgery. The primary outcome was MACE, a composite of stroke, revascularization, and hospitalization for myocardial infarction or heart failure. The secondary outcome was all-cause mortality. The cumulative incidence of MACE was estimated via a competing risk framework, while the cumulative incidence of mortality was estimated with the Kaplan-Meier method. Multivariate Cox proportional hazard regressions were fitted for all outcomes. Results: The cohort included 12,706 LEP patients (28.8% female) and 393,612 English-proficient patients (33.2% female). Differences in baseline characteristics included age, race, and comorbidity burden. The unadjusted cumulative incidence of MACE was higher in LEP patients, but all-cause mortality was lower (Figure 1). Over the follow-up period, the incidence rate of MACE for English proficient patients vs LEP was 185 vs 219 per 1000 patient years and 39 vs 36 per 1000 patient years for mortality. The adjusted hazard ratio for MACE was 0.97 (95% CI: 0.94 - 1.01, p = 0.19) and 0.89 (95% CI: 0.83 - 0.95, p <0.001) for mortality. Conclusions: LEP was associated with higher unadjusted cumulative incidence of MACE and lower mortality, but only the association with mortality persisted after regression analysis. Our findings highlight the need for further research into the impact of language proficiency on outcomes after cardiac surgery and the potential benefit of targeted interventions to address language-related disparities.
Abstract 4369381: Regulation of Nav1.5 Channel Surface Expression and Function by Sorbs2 in Atrial Cardiomyocytes
Ou, Mengchan, Zou, Tian, Sun, Xiaojing, Lee, Hon-Chi, Lu, Tong , Lu, Tong

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4369381 Get It

Background: Voltage-gated Nav1.5 channel, encoded by SCN5A , is essential for initiation and propagation of action potentials (AP) in atria. Nav1.5 channelopathy is strongly associated with arrhythmogenesis, including atrial fibrillation. Sorbin and SH3 domain-containing protein 2 (Sorbs2), encoded by SORBS2 , is an important cytoskeletal protein for maintaining atrial structural and electrical integrity. However, the specific mechanisms through which Sorbs2 modulates Nav1.5 function in atria is unknown. Hypothesis: Sorbs2 modulates atrial Nav1.5 expression and function through direct protein-protein interaction. Methods: We created the cardiac-specific Sorbs2 knockout ( c-Sorbs2 KO) mice. We determined the mechanisms by which Sorbs2 regulates Nav1.5 channel expression and function by performing electrophysiological experiments using atrial cells and tissues from control and c-Sorbs2 KO mice, in conjunction with molecular biological studies and in silico analysis. Results: c-Sorbs2 KO mice at 8-10 months showed marked left atrial (LA) enlargement, and ECG showed significantly prolonged P-R durations. Compared to wild-type controls, intracellular recordings in LA tissues isolated from c-Sorbs2 KO mice showed reduced AP amplitude, decreased upstroke velocity, prolonged AP duration at 90% repolarization and effective refractory period, spontaneous atrial tachycardias and triggered activity. Patch-clamp recordings in freshly isolated atrial cardiomyocytes showed a significantly reduced peak sodium current density in c-Sorbs2 KO mice (-12.0 ± 1.6 pA/pF at -45 mV, n = 10), compared to controls (-21.3 ± 4.0 pA/pF at -45 mV, n = 12, p < 0.05). Also, the steady-state activation and inactivation curves of Nav1.5 channel were rightward shifted in c-Sorbs2 KO atrial cardiomyocytes. Molecular docking analysis showed that the Sorbs2 SH3 domain interacts directly with the voltage-sensing domain of Nav1.5. Co-immunoprecipitation assays confirmed the physical interactions between Nav1.5 and the C-terminal SH3 domain of Sorbs2. Furthermore, results from membrane biotinylation study demonstrated that deletion of the SH3 domains of Sorbs2 significantly reduced Nav1.5 surface expression in HEK293 cells. Sorbs2 interacts directly with Nav1.5 through its SH3 domain, playing a key role in regulating Nav1.5 channel gating kinetics and surface expression in atrial cardiomyocytes. Loss of Sorbs2 results in Nav1.5 channelopathy and contributes to atrial electrical remodeling.
Abstract 4341827: Double Trouble — Exploring Mental Health Issues in Patients with Spontaneous Coronary Artery Dissection (SCAD) and Fibromuscular Dysplasia (FMD)
Coutinho, Thais , Madan, Mina , So, Derek , Saw, Jacqueline , Wells, George A. , Sun, Louise Y. , Robert, Helen Mary, Lappa, N., Tulloch, Heather , Maukel, Lisa‐Marie , Mulvagh, Sharon L. , Pacheco, Christine , Bouchard, Karen , Reed, Jennifer L. , Liu, Shuangbo , Robert, Helen

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4341827 Get It

Background: Spontaneous Coronary Artery Dissection (SCAD) is a cause of acute coronary syndrome, particularly among women, and is associated with psychological distress, including depression, anxiety, and post-traumatic stress (PTSD) symptoms. Fibromuscular dysplasia (FMD), a vascular condition that alters the arteries, is often found in patients with SCAD, adding complexity and uncertainty with a second serious diagnosis. This study examined the differences in mental health symptoms between SCAD survivors with and without FMD to better understand their unique psychosocial needs and inform interventions to enhance patient outcomes. Methods: Patients diagnosed with SCAD within the past 3 years were recruited from 6 Canadian cardiac hospitals. Participants completed questionnaires assessing socio-demographics, comorbidities, and validated psychological measures, including Patient Health Questionnaire-9 (PHQ-9) for depression, Generalized Anxiety Disorder-7 (GAD-7) for generalized anxiety, Cardiac Anxiety Questionnaire (CAQ) for cardiac-related anxiety, and PTSD Checklist (PCL-5) for PTSD symptoms. Differences in mental health outcomes between SCAD survivors with and without FMD were analyzed using t-tests for continuous variables and chi-square tests for categorical variables. Results: The study included 326 participants (92.9% female; mean age 53.3 years), with 67 participants (20.6%) having a confirmed diagnosis of FMD at the time of questionnaire completion (39.3% FMD at study completion). Post-SCAD, patients with FMD reported significantly higher scores than patients without FMD on the GAD-7 (6.4±5.9 vs. 4.7±4.9, p = .028), CAQ (29.9±13.1 vs. 26.0±12.3, p = .023), and PCL-5 (17.2±15.4 vs. 13.3± 14.0, p = .048). The proportion of SCAD survivors with FMD scoring in the clinically diagnostic range was significantly higher than those in patients without FMD: 32.8% vs. 20.8% for depression, 31.3% vs. 17.4% for anxiety, 64.2% vs. 49.2% for cardiac anxiety, and 25.4% vs. 11.6% for PTSD (all p < .05). Conclusions: Our findings suggest that SCAD survivors with comorbid FMD experience significantly higher distress —depression, generalized anxiety, cardiac-related anxiety, and PTSD symptoms—compared to those without FMD. Longitudinal research is needed to explore the role of these mental health concerns in long-term mental health and cardiac outcomes. Enhanced psychological interventions for those with FMD may be required.
Abstract 4366180: Sorbs2 Deficiency-induced Cardiac MyBP-C Downregulation Underlies Atrial Fibrotic Cardiomyopathy in Mice
Zou, Tian , Sun, Xiaojing , Lee, Hon-Chi, Zou, Tian, Lü, Tong

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4366180 Get It

Background: Cardiac myosin-binding protein C (cMyBP-C, encoded by MYBPC3 ) and Sorbin and SH3 domain-containing protein 2 (Sorbs2, encoded by SORBS2 ) are critical sarcomeric components that maintain cardiac structure and function. MYBPC3 and SORBS2 are linked to hypertrophic and dilated cardiomyopathies. But the relationship between Sorbs2 and cMyBP-C regulation, and their roles in the pathogenesis of atrial fibrotic cardiomyopathy (AFCM), remains unclear. Hypothesis: Sorbs2 acts as a cytoskeletal and RNA-binding protein that regulates cMyBP-C expression in atrial myocardium. Methods: We created the cardiac-specific Sorbs2 knockout ( c-Sorbs2 KO mice. We used next-generation RNA sequencing, molecular biology techniques, and in silico analysis to study how Sorbs2 regulates cMyBP-C expression in the atria of c-Sorbs2 KO mice. Results: Compared to age-matched wild-type (WT) mice at 8-9 months of age, the c-Sorbs2 KO male exhibited significant left atrial (LA) enlargement (diameter: 2.41±0.11 mm vs 1.82 ± 0.05 mm in WT; n = 8; p < 0.001) and severe atrial fibrosis (fibrotic area: 12.29±1.73 vs 2.83 ± 0.41% in WT; p < 0.001), accompanied by marked reductions in both mRNA and protein levels of cMyBP-C in LA. In vitro knock-down of Sorbs2 by 60% via shRNA led to an 86.3% decrease in cMyBP-C protein levels, while a 3-fold Sorbs2 overexpression via adenoviral transduction resulted in a 1.4-fold increase in cMyBP-C protein levels in HL-1 cells . cMyBP-C mRNAs were identified in the ribonucleoprotein complexes immunoprecipitated with anti-Sorbs2 antibodies from cardiomyocyte lysates. Loss of Sorbs2 significantly reduced the half-life of cMyBP-C mRNA (from 2.1 hrs in WT to 1.2 hrs in KO). Co-immunoprecipitation with truncated Sorbs2 constructs showed that the C-terminal SH3 domains of Sorbs2, but not the N-terminal SoHo domain, interacted with cMyBP-C protein. Molecular docking and modeling showed hydrophobic interactions and hydrogen bonds between residues H906 and G907 in the SH3 domain of Sorbs2 and residue A954, P955 and T957 in the SH3-binding motif (949-MA P GA P VT-957) of cMyBP-C with a weighted score of -1036 using ClusPro online service. Conclusions: Sorbs2 regulates cMyBP-C expression through direct interaction with both cMyBP-C mRNA and protein. Loss of Sorbs2 results in reduced cMyBP-C expression, atrial fibrosis, and chamber enlargement, revealing a novel Sorbs2/cMyBP-C axis underlying AFCM pathogenesis.
Investigating the Effects of Long-Term Fine Particulate Matter Exposure on Autism Spectrum Disorder Severity: Evidence from Multiple Analytical Approaches
Dou, Jianrui, Xie, Ruijin , Xu, Hua, Xiao, Xue, Luo, Yufan , Xu, Shiyu , Xiao, Wei, Wu, Dongqin , Zhang, Linpei , Sun, Chenyu , Liu, Yueying , Xie, Ruijin , Pan, Qiyang, Sun, Chenyu , Dou, Jianrui, Zhang, Kaiyue , Pan‐Hammarström, Qiang , Wang, Bin , Liu, Yueying

Mayo Clinic

Toxics | October 30, 2025 | Volume: 13 | Issue: 11 | Pages: 922

10.3390/toxics13110922 | PMID 41304474 Get It

With rapid industrial expansion, air pollution’s adverse neurological effects have gained increasing attention. Children face a greater risk of neurological damage because of their higher breathing rates, developing brains, and limited ability to detoxify harmful substances. Fine particulate matter has been identified as a primary neurotoxic contributor affecting developing brains. Strong evidence connects environmental pollutant exposure to the prevalence of Autism Spectrum Disorder (ASD), a neurodevelopmental condition marked by lasting difficulties with social communication and interaction. This study explores the association between long-term PM2.5 exposure and ASD symptom exacerbation, investigating underlying mechanisms. We hypothesize that long-term PM2.5 exposure exacerbates ASD symptoms through neuroinflammatory activation, leading to neuronal damage and impaired synaptic plasticity. Our investigation employs three complementary approaches: First, integrated analysis combining Global Burden of Disease data with Mendelian randomization demonstrates a significant association between PM2.5 exposure and increased ASD severity risk. Second, utilizing the China High-Resolution Air Pollution Database in conjunction with cohort studies, we provide evidence that ambient air pollution substantially influences autism severity, with PM2.5 identified as the predominant environmental determinant. Third, through network toxicology, single-cell transcriptomics, and animal experimentation, we demonstrate that chronic PM2.5 exposure exacerbates valproic acid-induced autism-like behaviors in murine models, identifying CTNNB1, PTEN, CCR2, AKT1, and mTOR as potential core mediating genes. Importantly, these findings represent preliminary results. Several potential confounding factors such as co-exposure to other pollutants and socioeconomic variables have not been fully addressed. While our multi-modal approach provides converging lines of evidence, further validation in larger, more diverse populations with refined control of confounders will be essential to establish causality and elucidate mechanisms. Nonetheless, these early insights advance our understanding of PM2.5-induced neurotoxicity in the context of ASD and offer timely, albeit preliminary, evidence to inform public health policy.
Targeting PD-L1-CMTM6 interactions in myeloid cells triggers PD-L1 degradation and enhances cytotoxic T-cell expansion
Hsu, Michelle A. , Harrington, Susan M. , Lin, Crystal Yan , Hirdler, Jacob B. , Mao, Zhiming , Dellacecca, Emilia R. , Ashton, Dallin S. , Sun, N , Lin, Crystal, Sun, Nicholas D, Lucien, Fabrice , Dong, Haidong , Liu, Xin , Barham, Whitney , Pavelko, Kevin D. , Zhang, Wenjing , Lancaster, Jessica N. , Lucien, Fabrice , Dong, Haidong

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 28, 2025 | Volume: 13 | Issue: 10 | Pages: e012164

10.1136/jitc-2025-012164 | PMID 41151837 Get It

Background Immune checkpoint therapies targeting programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) have been met with limited clinical responses in the treatment of patients of varying cancer types. Current US Food and Drug Administration (FDA)-approved therapies function to prevent PD-1 binding to PD-L1, thereby preventing T-cell suppression. However, these therapies fail to prevent PD-L1 intrinsic signaling and recycling, which can render these treatments ineffective. Moreover, most research primarily focuses on how these antibodies affect tumor cells and their interactions with T cells. Myeloid cells, which also express PD-L1 and influence T-cell responses, are integral to the efficacy of these therapies. However, strategies that can target these cells to boost antitumor responses have not been effective. Methods Our group has developed a new anti-PD-L1 antibody (H1A), which disrupts PD-L1 recycling and redirects it towards degradation. Due to the loss of available PD-L1 protein, H1A effectively prevents PD-L1 intrinsic signaling. Using in vivo humanized PD-1/PD-L1 mouse tumor models, we evaluated the therapeutic efficacy of H1A against current FDA-approved PD-L1 blocking antibodies. Using human-derived immune cell in vitro assays, we pinpoint the biological consequences of H1A-induced PD-L1 degradation in myeloid cells. Results H1A demonstrated improved tumor control and established immunological memory responses in vivo in the treatment of tumors with moderate immunogenicity that are less responsive to current immunotherapies. This was supported by enhanced activation of myeloid cells (major histocompatibility complex (MHC)-II and CD80) and frequencies of effector T-cell populations found intratumorally. Human myeloid cells treated with H1A were also observed to have increased activation (MHC-II and CD80) and cytokine secretion. Similar to our in vivo findings, human peripheral blood lymphocyte cultures demonstrated increased frequencies of effector T-cell populations and greater tumor cell killing. Conclusions This work highlights the importance of targeting PD-L1 recycling and intrinsic signaling, specifically in myeloid cells, to boost antitumor responses. Our studies suggest that H1A can provide a solution to the lack of responses seen with current therapeutics, while also revealing previously unknown intrinsic functions of PD-L1 in myeloid cells.
CDK12-Mediated Phosphorylation of FOXA1 Promotes Prostate Cancer Progression via the MDM2–p53 Axis
Yan, Binyuan, Huang, Mengjun, Wang, Jinxiang , Lei, Hanqi, Tong, Tongyu , Xu, Bin , Cao, Fei, Teng, Qiliang, Mao, Wenjun, Yan, Binyuan , Pang, Jun , Yan, Binyuan , Yan, Binyuan, Huang, Mengjun, Lei, Hanqi, Teng, Qiliang, Huang, Jinsheng , Guan, Yupeng , Mao, Wenjun, Huang, Haojie , Pang, Jun

Mayo Clinic

Research | October 27, 2025 | Volume: 8 | Issue: No issue available | Pages: No page available

10.34133/research.0990 | PMID 41395253 Get It

Prostate cancer (PCa) progression is driven by intricate molecular mechanisms involving dysregulated signaling networks and posttranslational modifications of key regulatory proteins. In this study, we identify a novel oncogenic pathway wherein cyclin-dependent kinase 12 (CDK12) physically interacts with and phosphorylates forkhead box A1 (FOXA1) at serine 234 (S234). Phosphorylation at this residue markedly enhances FOXA1 transcriptional activity, leading to up-regulation of downstream targets including murine double minute 2 (MDM2), a critical negative regulator of the p53 tumor suppressor. Mechanistically, this CDK12–FOXA1–MDM2 axis destabilizes p53, attenuates apoptotic signaling, and promotes PCa cell survival and proliferation. Therapeutic targeting of CDK12 using the small-molecule inhibitor THZ531 or RNA interference effectively abrogates FOXA1 phosphorylation, restores p53 stability, reactivates apoptotic pathways, and suppresses tumor growth. Notably, the identification of S234 as a functional phosphorylation site in FOXA1 reveals a previously uncharacterized posttranslational regulatory mechanism in PCa biology. These findings establish the CDK12–FOXA1–MDM2 axis as a pivotal driver of PCa progression and underscore the therapeutic potential of targeting FOXA1 phosphorylation to restore tumor suppressor function and induce apoptosis in PCa. Our work provides a mechanistic framework for developing precision therapies aimed at disrupting this oncogenic cascade in PCa.
Circulating cell‐free DNA methylation biomarkers for hepatocellular carcinoma risk prediction in HIV ‐positive Nigerian population
Zheng, Yinan , Han, Jingzhe , Qu, Yishu , Wang, Jun , Okeke, Edith, Davwar, Pantong , Duguru, Mary, Nyam, David, Oyeleke, Ganiyat K. , Sulaimon, Akanmu A., Hawkins, Claudia , Badmos, Kabir, Gursel, Demirkan, Silas, Olugbenga A. , Kocherginsky, Masha , Sun, Zequn , Achenbach, Chad J. , Yang, Hushan , Sagay, Atiene S. , Roberts, Lewis R., Hou, Lifang , Roberts, Lewis R. , Yang, Hushan , Roberts, Lewis R , Zheng, Yinan , Hou, Lifang , Wang, Jun , Joyce, Brian , Odeghe, Emuobor , Lesi, Olufunmilayo , Imade, Godwin , Abdulkareem, Fatimah Biade , Wei, Jian‐Jun , Kim, Kwang‐Youn A. , Zhang, Xuehong , Ogunsola, Folasade Tolulope , Murphy, Robert L. , Roberts, Lewis R.

Mayo Clinic

International Journal of Cancer | October 23, 2025 | Volume: 158 | Issue: 5 | Pages: 1281-1291

10.1002/ijc.70204 | PMID 41129333 Get It

Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally, with particularly high burdens among people living with HIV (PLWH) in low‐resource settings like Nigeria. Effective early detection remains a major challenge due to limited access to imaging‐based surveillance and the low sensitivity of current biomarkers such as alpha‐fetoprotein (AFP). We conducted an epigenome‐wide association study (EWAS) of circulating cell‐free DNA (ccfDNA) methylation in a Nigerian cohort of HIV‐positive individuals ( n = 245), spanning HCC, cirrhosis (FibroScan ≥12.3 kPa), fibrosis (FibroScan ≥7.6 and <12.3 kPa), and HCC‐free without fibrosis (FibroScan <7.6 kPa) groups. Using random forest modeling, we developed and evaluated a ccfDNA methylation classifier (ccfDNAmRF) for HCC risk prediction. We identified 73 CpG sites significantly associated with HCC (false discovery rate <0.01). The ccfDNAmRF model demonstrated strong discriminatory power, achieving 100% sensitivity and 80%–91% specificity for distinguishing HCC from cirrhosis, fibrosis, and HCC‐free groups (area under the curve [AUC]: 92%–97%). Combining ccfDNA methylation risk scores with AFP further improved classification accuracy (AUC up to 98.5%). Notably, ccfDNA methylation patterns displayed clear dose–response relationships across the disease spectrum, supporting their utility for early‐stage detection and risk stratification. Our findings highlight the promise of ccfDNA methylation biomarkers as a non‐invasive, blood‐based screening tool for improving early identification of HCC cases among PLWH.
SUN-478 Assessment Of Cortisol And Dexamethasone Concentrations In Capillary Blood
Torres, Camila A Villavicencio, Ahmadian, Sarina , Moehnke, Kayla , Fell, Vanessa , Grebe, Stefan K. , Taylor, Robert L, Maus, Anthony , Bancos, Irina

Mayo Clinic

Journal of the Endocrine Society | October 23, 2025 | Volume: 9 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvaf149.443 Get It

Abstract Disclosure: C.A. Villavicencio Torres: None. S. Ahmadian: None. K. Moehnke: None. V.M. Fell: None. R.L. Taylor: None. S.K. Grebe: None. A.D. Maus: None. I. Bancos: None. Background: Evaluation of adrenal disorders relies on total cortisol measurements at baseline or during dynamic testing. Accurate cortisol assessment that avoids phlebotomy may simplify the work up of adrenal disorders, decrease healthcare costs, and improve patient experience. Objectives: We aimed to compare cortisol and dexamethasone concentrations between venipuncture-based (clinical) and capillary blood samples. Methodology: We conducted a cross-sectional study (July 2024-April 2025) of adults undergoing standard-of-care cortisol measurements. Capillary blood samples were collected alongside clinical samples. Capillary measurements included total cortisol and dexamethasone (mass spectrometry). Clinical samples were tested for total cortisol (Roche immunoassay) and dexamethasone (mass spectrometry). Results: Of 318 patients (243, 77% women, median age 53 years, IQR 39-66), 227 (71%) underwent dexamethasone suppression test (DST) and 88 (28%) cosyntropin stimulation test (CST). Capillary blood collection failed in 13 (4%) patients. In patients undergoing DST, median post-dexamethasone serum cortisol was 1.3 mcg/dL (IQR 0.8-2.2), and serum dexamethasone was 0.41 mcg/dL (IQR 0.27-0.59), while median capillary cortisol was 1.5 mcg/dL (IQR 1-2.5), and capillary dexamethasone was 0.33 mcg/dL (IQR 0.21-0.51). Capillary cortisol (r=0.95, 95% CI [0.93, 0.96], p&lt;.0001) and capillary dexamethasone (r=0.93, 95% CI [0.90, 0.95], p&lt;.0001) showed strong correlation with their respective clinical measurements. In patients undergoing CST, median baseline serum cortisol was 7.5 mcg/dL (IQR 5-10), and median baseline capillary cortisol was 8.5 mcg/dL (IQR 6-12). Median post-CST 60-minute serum cortisol was 23 mcg/dL (IQR 20-25), while capillary cortisol was 25 mcg/dL (IQR 21-28). Baseline (r=0.77, 95% CI [0.66, 0.85], p&lt;.0001) and post-CST 60-minute capillary cortisol (r=0.88, 95% CI [0.81-92], p&lt;.0001) strongly correlated with clinical measurements. Post-dexamethasone cortisol in paired DST samples showed that capillary measurements were higher than serum cortisol (median difference 0.20 mcg/dL (95% CI [0.12, 0.42], p&lt;.0001), while paired capillary dexamethasone concentrations were lower than serum dexamethasone concentrations (median difference 0.04 mcg/dL (95% CI [0.03, 0.07], p&lt;.0001). In CST, paired baseline capillary and serum cortisol concentrations were similar (median difference 0.10 mcg/dL, 95% CI [0.3, 0.3], p=.3660), while paired post-CST 60-minute capillary cortisol was higher than serum cortisol by a median of 2.8 mcg/dL (95% CI [2, 3.2], p&lt;.0001). Conclusion: Capillary cortisol and dexamethasone concentrations demonstrate excellent correlation with venipuncture-based measurements. Following validation with at-home collection, capillary blood measurements may serve as an alternative for evaluating adrenal disorders. Presentation: Sunday, July 13, 2025